Menu Search
Equities

RAPT Therapeutics Inc

0RA:MUN

RAPT Therapeutics Inc

Actions
  • Price (EUR)2.66
  • Today's Change0.04 / 1.53%
  • Shares traded2.50k
  • 1 Year change-75.60%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-120.43m
  • Incorporated2015
  • Employees122.00
  • Location
    RAPT Therapeutics Inc561 Eccles AveSOUTH SAN FRANCISCO 94080-1906United StatesUSA
  • Phone+1 (650) 489-9000
  • Fax+1 (302) 531-3150
  • Websitehttps://rapt.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.